PT-141 Reconstitution Calculator

Yes. PT-141 is bremelanotide, a synthetic cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R). The FDA approved it in 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), delivered as a 1.75 mg subcutaneous autoinjector. Approval followed two phase 3 double-blind, placebo-controlled trials (RECONNECT) (RCT). It is used on-demand for HSDD in women, though it is frequently obtained outside this indication. Black-market formulations sold as "PT-141" are widely analyzed and not quality-controlled.

Subcutaneous injection is the approved route (1.75 mg; community dosing typically 0.5–2 mg) (community protocol). Onset ranges from ~45 minutes to a few hours; the approved label limits use to once per 24 hours and ≤8 doses monthly. Oral bioavailability is negligible: bremelanotide (1.03 kDa) is degraded in the GI tract, so only 26% relative bioavailability was achieved even with a specialized buccal suction patch. An early intranasal formulation at 20 mg showed modest subjective desire effects in 18 women but no significant change in vaginal vasocongestion (RCT); the intranasal program was ultimately abandoned in favor of SC delivery. Lyophilized powder is usually reconstituted with bacteriostatic water and refrigerated; stability is manufacturer-dependent (community protocol).

Nausea is the dominant adverse event, reported by ~40% of treated women in the RECONNECT trials, followed by flushing, headache, and injection-site reactions; discontinuation for adverse events reached roughly 18% versus ~2% for placebo across the development program (RCT). Transient blood pressure increases were observed; ambulatory monitoring found no clinically meaningful sustained hypertension overall, but monitoring is recommended for patients with elevated baseline BP (RCT). Alcohol coadministration increased nausea and vomiting compared with bremelanotide alone (phase 1 RCT); alcohol use around dosing is discouraged. Community protocol pairs dosing with an ondansetron-class antiemetic 30–60 minutes prior to mitigate nausea. Hyperpigmentation and darkening of nevi can occur with melanocortin activation (mechanistic).

An open-label extension of the phase 3 program supports maintained efficacy and safety through 52 weeks of on-demand use (RCT). Efficacy endpoints were measured over 24 weeks in the pivotal trials. Efficacy magnitude is contested: independent reanalysis of RECONNECT data found nil-to-small effect sizes and weak validity evidence for several endpoints; meta-analytic summary still reports improvements in desire and arousal subscales and reduced distress. Practically, an 8-week trial at the minimum effective dose is reasonable before deciding whether to continue; discontinue if nausea persists beyond 2 weeks (community protocol).

Both are FDA-approved for premenopausal HSDD but differ in mechanism and regimen: bremelanotide acts centrally at MC3R/MC4R and is injected PRN, whereas flibanserin is a daily oral serotonin/dopamine modulator requiring nightly dosing. Bremelanotide is not subject to flibanserin's formal alcohol contraindication, but alcohol still increases bremelanotide-related nausea and vomiting, so alcohol use around dosing is discouraged; it also avoids flibanserin's hypotensive interaction. Flibanserin avoids injection use and typically has milder, though daily, side effects (observational reviews). In meta-analysis, both improve desire and reduce distress; bremelanotide additionally improved the arousal subscale. Selection is driven by tolerability of nausea/injection versus daily-dosing adherence and alcohol restrictions.

Bremelanotide is a prescription drug (not controlled under the Controlled Substances Act) with REMS-free distribution through licensed pharmacies. Unregulated "research peptide" products sold online are not approved formulations; seized-market analysis confirms real-world samples of bremelanotide and close analogs exist outside regulatory supply chains, with no purity guarantee. Degradant characterization shows the cyclic peptide is susceptible to epimerization, making storage conditions relevant to product integrity. Legal exposure depends on jurisdiction and whether the product is obtained with a prescription; ordering research chemicals for human injection generally falls outside FDA-sanctioned use (regulatory).